SCHEMBL13336207

SCHEMBL13336207

C#Cc1ccc2nc(Nc3cc(CN4CCS(=O)(=O)CC4)cc(-c4cnn(C)c4)c3)ncc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 4/20 0.41
▸ MAP4K3 Q8IVH8 1/20 0.41
▸ IRAK1 P51617 2/20 0.39
▸ TTK P33981 1/20 0.39
▸ EGFR P00533 1/20 0.38
▸ ERBB2 P04626 1/20 0.38
▸ ERBB4 Q15303 1/20 0.38
▸ JAK2 O60674 5/20 0.37
▸ JAK3 P52333 5/20 0.37
▸ FGFR1 P11362 1/20 0.36
▸ FGFR2 P21802 1/20 0.36
▸ FGFR4 P22455 1/20 0.36
▸ FGFR3 P22607 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ PTK2 Q05397 3/20 0.36
▸ WNT1 P04628 2/20 0.36
▸ GSK3B P49841 2/20 0.36
▸ DYRK1A Q13627 2/20 0.36
▸ JUN P05412 1/20 0.36
▸ MAPK8 P45983 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13335984 0.92 MAP4K1 (0.45) MAP4K1MAP4K3EGFRERBB2ERBB4
SCHEMBL13336034 0.91 MAP4K1 (0.42) MAP4K1MAP4K3EGFRERBB2ERBB4
SCHEMBL13336031 0.90 MAP4K1 (0.42) MAP4K1MAP4K3EGFRERBB2ERBB4
SCHEMBL1570539 0.89 SYK (0.45) MAP4K1MAP4K3IRAK1TTKEGFR
SCHEMBL13574033 0.89 MAP4K1 (0.43) MAP4K1MAP4K3IRAK1TTKJAK2
SCHEMBL13336192 0.88 MAP4K1 (0.43) MAP4K1MAP4K3IRAK1TTKJAK2
SCHEMBL13336165 0.87 GRM2 (0.41) MAP4K1MAP4K3TTKEGFRERBB2
SCHEMBL13336282 0.86 MAP4K1 (0.39) MAP4K1MAP4K3EGFRERBB2ERBB4
SCHEMBL13336322 0.85 GRM2 (0.42) MAP4K1MAP4K3EGFRERBB2ERBB4
SCHEMBL13336186 0.85 MAP4K1 (0.42) MAP4K1MAP4K3EGFRERBB2ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121052-A1 Novel compounds for treating proliferative diseases JAIN RAMA 2010-05-13 — — US disclosed
US-20100121052-A1 Novel compounds for treating proliferative diseases JAIN RAMA 2010-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121052-A1 Novel compounds for treating proliferative diseases PDK1, PDK2, PDK3 MAP4K1 112/4885MAP4K3 103/4885IRAK1 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback